I'll research AMETEK (AME) before writing the earnings preview. Let me start by gathering recent filings, transcripts, and market data.Let me read the most recent quarter's earnings release and call transcript.Let me get recent stock performance and check for any recent news and analyst expectations.Let me get the year-ago Q2 2025 base numbers and any very recent news.I have what I need. Here's the earnings preview.
Report date: Wednesday, August 4, 2026 (before market open; conference call 8:30 AM ET) Event: Q2 2026 Earnings Call
AMETEK heads into Q2 with strong momentum. Q1 2026 was a genuine standout: sales of $1.93 billion (+11%, +5% organic), adjusted EPS of $1.97 (+13%) that beat the top of guidance ($1.85–$1.90), record EBITDA of $620M, and — most importantly — record orders of $2.2 billion, up 23% (+22% organic), driving a record backlog of $3.87 billion. That order strength is the single most important data point going into Q2, because it de-risks the back half of the year and gives management flexibility to keep raising guidance.
Management framed Q1 as the long-awaited inflection in EIG's short-cycle businesses (process instrumentation and power) finally catching up to the strength already visible in EMG — a dynamic Zapico had been signaling for a couple of quarters ("EMG picks up, EIG follows 6–9 months later"). If Q2 orders confirm this is durable rather than a one-quarter, large-order-driven spike, the bull case gets stronger.
| Metric | Q2 2026 Guide | Q2 2025 Actual | Implied Y/Y |
|---|---|---|---|
| Sales | Up high single digits | $1.778B | ~$1.92–1.94B |
| Adjusted EPS | $1.96 – $2.00 (mid $1.98) | $1.78 | +10% to +12% |
| GAAP EPS | $1.73 – $1.77 | $1.55 | — |
Full-year 2026 guide (raised at Q1): Adjusted EPS $7.94–$8.14 (up 7–10% vs. ~$7.41 in 2025), sales up high single digits, organic up mid-single digits. Note the full-year midpoint (~$8.04) implies roughly $4.10 of EPS across 2H after ~$3.95 in 1H — i.e., the guide bakes in essentially flat sequential progression, which looks conservative given the order book.
Key point on conservatism: The guide assumes only ~35% core incremental margins and ~50 bps of core margin expansion for the year, versus the >50% core incrementals and +160 bps core margin actually delivered in Q1. This is a classic AMETEK sandbag — worth watching whether Q2 again blows past it.
A. Orders and book-to-bill. After a +23% order quarter, the debate is decel vs. sustainability. Management explicitly said Q1 was not pull-forward and expects "some larger orders" to continue, but also cautioned against extrapolating another 20%+ print. A book-to-bill still comfortably above 1.0 and organic orders sustaining double digits would be a strong signal. Any sharp order deceleration — even off a tough comp — will be scrutinized.
B. Margins / incrementals. EMG was the star in Q1 with +410 bps core margin on double-digit organic growth. Watch whether EMG can sustain 25%+ operating margins and whether EIG margins re-accelerate as its volumes recover. The bar for a "beat" is core incrementals well above the 35% embedded in guidance.
C. Price/cost and tariffs. Management is "laser-focused" on input costs and expects to fully offset inflation, including tariffs, with pricing. Any commentary that price/cost is getting tighter, or that tariffs are pressuring specific businesses, would be a negative surprise.
D. Another guidance raise. AMETEK raised full-year guidance at Q1. Given the backlog and beat-and-raise cadence, the market will likely expect another raise. A mere reaffirmation could be read as cautious; the question is magnitude.
E. M&A / capital deployment. This is arguably the biggest swing factor for the stock: - First Aviation Services (~$80M sales, defense MRO + proprietary parts) was signed in Q1 — watch for a closing update. - Management touted "well over $5 billion" of deployable capacity at ~0.7x net debt/EBITDA, with M&A as the #1 priority. - There were unconfirmed media reports (WSJ) of a potentially large deal — bigger than AMETEK's typical bolt-ons. Management won't comment on rumors, but any signal on a larger transaction would materially move the stock. Zapico framed larger deals as a strategic differentiator "over the next few years."
F. End-market color. In Q1 the standouts were A&D (raised to ~+10% for the year; defense "knocking it out of the park" — UAVs, missile defense, naval/submarine, space), power/data center (RTDS data center simulation wins), semiconductor (Abaco ruggedized computing into AI-driven semi cap equipment), and nuclear (commercial + defense). Watch for: - Medical (~20% of sales): Q1 up low double digits led by Paragon, but tougher comps in 2H — management guided full-year medical to mid-single digits. - Commercial aerospace aftermarket: management flagged this as the one area to watch (fuel availability/cost, international exposure), though it's <2% of sales and the U.S. remains insulated. - EMG comps get harder in 2H — expect organic growth to moderate toward mid-single digits on an exit-rate basis.
G. Geographic/macro read. Q1 saw balanced growth: U.S. and international both mid-single digits, Asia strongest (China up high-teens on process/power). Middle East is only ~2% of sales; ~$15M of Q1 orders slipped on regional disruptions but no cancellations. Investors will want confirmation demand remains broad-based and China holds up.
AME closed at ~$243.81 on Aug 3, near 52-week highs and up ~16.6% YTD (from ~$209 at the start of 2026). The stock has re-rated through the year on the order inflection and M&A optionality. Notably, its outperformance has been steadier than peer Roper (ROP), which has been more volatile in 2026.
With the stock near highs and a beat-and-raise clearly the consensus expectation, the bar is high. AMETEK's premium multiple leaves little room for disappointment on orders or margins. The setup favors continued execution being necessary but perhaps not sufficient for further upside — the upside catalysts are likely (1) a larger-than-guided EPS raise and (2) a needle-moving acquisition announcement.
Positive surprise would look like: organic orders sustaining double digits (book-to-bill >1.0), EPS at/above $2.00, core incrementals >40%, another full-year raise toward/above $8.14, and progress on a sizable acquisition.
Negative surprise would look like: sharp order deceleration off the Q1 record, EIG margin softness, price/cost tightening from tariffs, medical/EMG comp-driven slowing bleeding into orders, or a guide that's merely reaffirmed while the stock trades at highs.
Given AMETEK's long track record of conservative guidance and clean execution (record backlog, 107% FCF conversion, 0.7x net leverage, unblemished no-goodwill-write-off history), the base case is another beat-and-raise. The real question for the stock is whether that's already priced in — making order durability and M&A news the true swing factors.
Sources: AMETEK Q1 2026 earnings release and call transcript (Apr 30, 2026); Q2 2025 earnings release (Jul 31, 2025); historical price data through Aug 3, 2026. No material company-specific news items were found in the days immediately preceding this report.
This is an informational research summary, not investment advice.